SCHEMBL3628178

SCHEMBL3628178

CC(C)c1ccc(CC(=O)N2CCCCc3cc(C(O)(C(F)(F)F)C(F)(F)F)ccc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H3 Q13133 5/20 0.47
THRB P10828 1/20 0.46
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
TP53 P04637 2/20 0.43
POLB P06746 1/20 0.43
RORC P51449 4/20 0.42
NR1H2 P55055 2/20 0.42
NR1I2 O75469 1/20 0.42
IDO1 P14902 1/20 0.42
KCNH2 Q12809 1/20 0.42
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
LMNA P02545 1/20 0.41
NOTUM Q6P988 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13317314 0.92 THRB (0.48) NR1H3THRBALDH1A1MAPTTP53
SCHEMBL15108392 0.90 THRB (0.44) NR1H3THRBALDH1A1MAPTTP53
SCHEMBL3620198 0.89 NR1H3 (0.49) NR1H3ALDH1A1MAPTTP53POLB
SCHEMBL3617712 0.89 NR1H3 (0.49) NR1H3ALDH1A1MAPTRORCNR1H2
SCHEMBL3624100 0.89 NR1H3 (0.51) NR1H3ALDH1A1MAPTRORCNR1H2
SCHEMBL3621272 0.88 NR1H3 (0.58) NR1H3ALDH1A1MAPTPOLBRORC
SCHEMBL3615126 0.88 RORC (0.55) NR1H3RORCNR1H2NR1I2
SCHEMBL3628809 0.88 NR1H3 (0.50) NR1H3ALDH1A1MAPTRORCNR1H2
SCHEMBL3623850 0.86 ALDH1A1 (0.61) NR1H3THRBALDH1A1MAPTTP53
SCHEMBL3625545 0.86 NR1H3 (0.47) NR1H3THRBALDH1A1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951676-B1 N-ACYL BENZAZEPINE DERIVATIVES AS LXR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-07-17 EP disclosed
EP-2392567-A1 BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS Bristol-Myers Squibb Company (US) 2011-12-07 EP disclosed
US-7741317-B2 LXR modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-22 US disclosed
US-7741317-B2 LXR modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-22 US disclosed
US-7741317-B2 LXR modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-22 US disclosed
EP-1951676-A2 LXR MODULATORS Brystol-Myers Squibb Company (US) 2008-08-06 EP disclosed
WO-2007050425-A2 LXR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-03 WO disclosed
US-20070093470-A1 LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed
US-20070093470-A1 LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed
US-20070093470-A1 LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093470-A1 LXR modulators NR1H2, NR1H3, RXRB NR1H3 2/4885THRB 50/4885ALDH1A1 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.